公开(公告)号：US20210395241A1

公开(公告)日：2021-12-23

申请号：US17252613

申请日：2019-07-02

申请人： Novartis AG

发明人： Gary GLICK ,  William R. Roush ,  Shankar VENKATRAMAN ,  Dong-Ming SHEN ,  Shomir GHOSH ,  Hans Martin SEIDEL ,  Luigi FRANCHI ,  David Guenther WINKLER ,  Anthony William OPIPARI ,  Jason KATZ

IPC分类号： C07D417/12 ,  C07D277/36 ,  C07C311/51 ,  A61K45/06

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20230416211A1

公开(公告)日：2023-12-28

申请号：US18319630

申请日：2023-05-18

申请人： NOVARTIS AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： C07D277/36 ,  C07D307/64 ,  C07D333/34 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/79 ,  C07D317/62 ,  C07D487/04

CPC分类号： C07D277/36 ,  C07D307/64 ,  C07D333/34 ,  C07C307/06 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/79 ,  C07D317/62 ,  C07D487/04 ,  C07C335/42

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:






or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20230062815A1

公开(公告)日：2023-03-02

申请号：US17496375

申请日：2021-10-07

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, JR. ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： C07D277/36 ,  C07D215/36 ,  C07D231/18 ,  C07D239/26 ,  C07D263/46 ,  C07D307/64 ,  C07D307/79 ,  C07D317/62 ,  C07D333/34 ,  C07D487/04 ,  C07C307/06

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20220267276A1

公开(公告)日：2022-08-25

申请号：US17252623

申请日：2019-07-02

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, Jr. ,  William R. ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： C07D221/16 ,  C07D277/36 ,  C07D417/12 ,  C07D213/75 ,  C07C335/42 ,  A61K45/06

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

公开(公告)号：US20230079631A1

公开(公告)日：2023-03-16

申请号：US17662863

申请日：2022-05-11

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, JR. ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： C07D265/30 ,  A61P1/00 ,  A61P11/00 ,  A61P19/08 ,  A61P35/00 ,  C07C381/10 ,  C07D209/26 ,  C07D211/78 ,  C07D215/06 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D261/08 ,  C07D263/46 ,  C07D277/36 ,  C07D317/50 ,  C07D333/34 ,  C07D401/12 ,  C07D409/12 ,  C07D417/12

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20230051589A1

公开(公告)日：2023-02-16

申请号：US17293781

申请日：2019-11-14

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, Jr. ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： A61K31/426 ,  A61K45/06 ,  A61K31/64 ,  C07D307/64 ,  C07D277/36 ,  A61K31/381 ,  C07D333/34 ,  C07D409/12 ,  A61K31/4436 ,  A61K31/18 ,  C07C381/10 ,  C07D231/18 ,  A61K31/415 ,  A61K31/36 ,  A61K31/4406 ,  A61K31/47 ,  C07D317/62 ,  C07D213/71 ,  C07D215/36 ,  C07D487/04 ,  C07D405/12 ,  A61K31/4188 ,  A61K31/397 ,  C07D205/04 ,  C07D295/096 ,  A61K31/5375 ,  C07D207/10 ,  A61K31/40 ,  A61K31/4015 ,  C07D207/12 ,  C07D333/72 ,  A61K31/451 ,  C07D211/24 ,  C07D495/04 ,  A61K31/4365 ,  A61P1/00 ,  A61P37/06

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20230059136A1

公开(公告)日：2023-02-23

申请号：US17293787

申请日：2019-11-14

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, Jr. ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： C07D277/80 ,  C07D333/34 ,  C07C311/57 ,  C07D231/12 ,  C07D317/60 ,  C07D307/36 ,  C07D417/12

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20220339169A1

公开(公告)日：2022-10-27

申请号：US17252630

申请日：2019-07-02

申请人： Novartis AG

发明人： Luigi FRANCHI ,  Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  Anthony William OPIPARI, Jr. ,  William R. ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN ,  David Guenther WINKLER

IPC分类号： A61K31/64 ,  C07K16/24 ,  A61K45/06 ,  C12Q1/6827 ,  C12N15/113

摘要： Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNFα agent and methods of determining the efficacy of treatment with an anti-TNFα agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNFα agent.